AKT1 and neoplasm: This finding provides a mechanistic explanation for the reduced sensitivity of LOX‐high tumours to platinum/paclitaxel drugs in the clinic and supports the strategy of combining LOX inhibitors with AKT inhibitors to overcome drug resistance.